Filter Results:
(358)
Show Results For
- All HBS Web
(705)
- Faculty Publications (358)
Show Results For
- All HBS Web
(705)
- Faculty Publications (358)
←
Page 18 of 358
Results
- April 1993 (Revised February 1996)
- Supplement
ALZA and Bio-Electro Systems (B1): Rights Offering Strategy
By: Josh Lerner and Peter Tufano
Supplements the (A) case. Describes the CEO's decision. View Details
Lerner, Josh, and Peter Tufano. "ALZA and Bio-Electro Systems (B1): Rights Offering Strategy." Harvard Business School Supplement 293-125, April 1993. (Revised February 1996.)
- April 1993 (Revised February 1996)
- Supplement
ALZA and Bio-Electro Systems (B2): The Rights Offering
By: Josh Lerner and Peter Tufano
Supplements the (A) case. Describes the implementation of the CEO's decision. View Details
Keywords: Intellectual Property
Lerner, Josh, and Peter Tufano. "ALZA and Bio-Electro Systems (B2): The Rights Offering." Harvard Business School Supplement 293-126, April 1993. (Revised February 1996.)
- April 1993 (Revised February 1996)
- Supplement
ALZA and Bio-Electro Systems (C): 1988-92
By: Josh Lerner and Peter Tufano
Supplements the (A) case. Describes the aftermarket performance of the units. View Details
Keywords: Performance
Lerner, Josh, and Peter Tufano. "ALZA and Bio-Electro Systems (C): 1988-92." Harvard Business School Supplement 293-127, April 1993. (Revised February 1996.)
- March 1993 (Revised May 1998)
- Teaching Note
ImmuLogic Pharmaceutical Corporation (Series) TN
By: Josh Lerner
Teaching Note for (9-293-066--071) and (9-293-087). View Details
Keywords: Pharmaceutical Industry
- 1993
- Article
Innovation and the Structure of High-Technology Industries
By: Josh Lerner
Lerner, Josh. "Innovation and the Structure of High-Technology Industries." Research on Technological Innovation, Management and Policy 5 (1993): 89–107.
- December 1992 (Revised September 1996)
- Case
ImmuLogic Pharmaceutical Corporation (Abridged)
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are... View Details
Keywords: Decisions; Initial Public Offering; Entrepreneurship; Going Public; Business Startups; Biotechnology Industry; Pharmaceutical Industry; United States
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (Abridged)." Harvard Business School Case 293-087, December 1992. (Revised September 1996.)
- October 1992 (Revised November 1997)
- Case
ImmuLogic Pharmaceutical Corporation (A): March 1991
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems... View Details
Keywords: Decisions; Entrepreneurship; Venture Capital; Banks and Banking; Initial Public Offering; Going Public; Perspective; Valuation; Biotechnology Industry; Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (A): March 1991." Harvard Business School Case 293-066, October 1992. (Revised November 1997.)
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter." Harvard Business School Supplement 293-067, October 1992. (Revised March 1993.)
- October 1992 (Revised April 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B2): Henry McCance
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B2): Henry McCance." Harvard Business School Supplement 293-068, October 1992. (Revised April 1993.)
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B3): Katherine Kirk
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B3): Katherine Kirk." Harvard Business School Supplement 293-069, October 1992. (Revised March 1993.)
- October 1992 (Revised April 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B4): Phillip Gross
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B4): Phillip Gross." Harvard Business School Supplement 293-070, October 1992. (Revised April 1993.)
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (C): April 1991
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (C): April 1991." Harvard Business School Supplement 293-071, October 1992. (Revised March 1993.)
- Teaching Interest
Owner/President Management Progam (Executive Education)
By: Josh Lerner
As business owners and entrepreneurs prepare to take their companies to the next level in a highly competitive global arena, they must be fully equipped to master a range of skills—from strategy development to financial management to team... View Details
- Teaching Interest
Private Equity and Venture Capital (Executive Education)
By: Josh Lerner
As equity markets appear to strengthen, interest rates remain low, and asset values look attractive, private equity firms are uniquely positioned to pursue new opportunities. This
- Forthcoming
- Article
The (Heterogenous) Economic Effects of Private Equity Buyouts
By: Steven J. Davis, John Haltiwanger, Kyle Handley, Ben Lipsius, Josh Lerner and Javier Miranda
The effects of private equity buyouts on employment, productivity, and job reallocation vary
tremendously with macroeconomic and credit conditions, across private equity groups, and by
type of buyout. We reach this conclusion by examining the most extensive... View Details
Keywords: Private Equity Buyouts; Impact; Private Equity; Economics; Employment; Performance Productivity; Wages
Davis, Steven J., John Haltiwanger, Kyle Handley, Ben Lipsius, Josh Lerner, and Javier Miranda. "The (Heterogenous) Economic Effects of Private Equity Buyouts." Management Science (forthcoming). (Earlier version distributed as National Bureau of Economic Research Working Paper No. 26371 and Harvard Business School Working Paper No. 20-030. Related discussion published as “Private Equity Buyout and Their Effects,” VoxEU, 2019.)
- Forthcoming
- Article
The Diffusion of New Technologies
By: Aakash Kalyani, Marcela Carvalho, Nicholas Bloom, Tarek Hassan, Josh Lerner and Ahmed Tahoun
We identify phrases associated with novel technologies using textual analysis of patents,
job postings, and earnings calls, enabling us to identify four stylized facts on the diffusion of jobs
relating to new technologies. First, the development of economically... View Details
Keywords: Technology; Geography; Innovation; R&D; Technological Innovation; Research and Development; Employment; Geographic Location
Kalyani, Aakash, Marcela Carvalho, Nicholas Bloom, Tarek Hassan, Josh Lerner, and Ahmed Tahoun. "The Diffusion of New Technologies." Quarterly Journal of Economics (forthcoming). (Pre-published online January 17, 2025. Earlier version distributed as National Bureau of Economic Research Working Paper No. 28999 and Harvard Business School Working Paper No. 21-114. Related discussion published as “How Disruptive Technologies Diffuse,” VoxEU, 2021.)
- Teaching Interest
Theoretical and Empirical Perspectives on Entrepreneurship (Doctoral)
By: Josh Lerner
Entrepreneurship—the formation and growth of new firms—is a complex phenomenon that has historically attracted relatively little academic attention. In recent years, however, scholars in a variety of disciplines have been devoting increasing attention to this topic.... View Details
- Teaching Interest
Venture Capital and Private Equity (MBA)
By: Josh Lerner
The growth of private equity internationally has been dramatic, to the point that the asset class has been both lauded as the savior and vilified as the cause of our current economic malaise. Over the past two decades, private equity- ranging from venture capital to... View Details
- ←
- 18